Navigation Links
First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
Date:5/23/2013

BEDFORD, Mass., May 23, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, today announced that the first large-scale observational study in a U.S. clinical practice comparing breast cancer screening with Hologic's 3D mammography technology (breast tomosynthesis) with conventional 2D mammography alone showed a significant reduction in recall rates and a sizeable increase in cancer detection, particularly invasive cancer, across all breast tissue densities. Published in the June issue of the American Journal of Roentgenology (AJR), the study evaluated recall, biopsy, cancer detection and invasive cancer detection rates in a community-based breast imaging practice. The study was issued online in advance of print on May 23, 2013.

The study, "Implementation of Breast Tomosynthesis in a Routine Screening Practice: An Observational Study"[i] was led by Stephen L. Rose , M.D., President and Founder of Rose Imaging, Medical Director of TOPS Comprehensive Breast Center, and Breast Radiologist affiliated with Memorial Hermann Health System in Houston, Texas. The analysis compared the outcomes of 2D mammography screening exams that were interpreted prior to the introduction of Hologic's 3D mammography, with screening exams after the introduction of 3D mammography into the practice.

The Rose study found that the use of Hologic's 3D mammography resulted in:

  • A  significant 38% drop in recall rates – from 8.7% to 5.5% (p < 0.001)
  • An 11%  drop in biopsy rates - from 15.2 to 13.5 per 1,000 screenings (p = 0.59)
  • A 35% increase in cancer detection rates - from 4.0 to 5.4 per 1,000 screenings (p = 0.18)
  • A 53% increase in invasive cancer detection rates - from 2.8 to 4.3 per 1,000 screening examinations (p = 0.07)
  • The study population included 13,856 women who had received conventional 2D mammography screening exams and 9,499 women who elected to receive a Hologic 3D mammography screening exam. The images were interpreted by one of six radiologists with an average 12 years of reading experience.  

    "The findings in the Rose paper demonstrate that Hologic 3D mammograms overcome many of the limitations of conventional mammography, namely missed cancers and unnecessary recalls," said Peter Soltani , Hologic Senior Vice President and General Manager, Breast Health. "The use of this groundbreaking technology when performing a screening exam allows radiologists to see distortions of the breast tissue in greater detail than with 2D mammography alone. This results in earlier detection of cancers when they are easier to treat and a reduction in false positives that may look worrisome on conventional digital mammography."

    The Rose study is the first large U.S. breast cancer screening trial to report its results in a peer-reviewed journal. The findings are consistent with and supplementary to the Oslo Tomosynthesis Screening Trial which was published in Radiology (online in advance of print January 7, 2013 and in print on April 4, 2013) and the Screening Tomosynthesis or Mammography (STORM) trial in Italy which was published in The Lancet Oncology (online in advance of print April 25, 2013).

    Hologic's 3D mammography technology has been approved for use in countries recognizing the CE mark since 2008. It was approved for use in the U.S. for breast cancer screening and diagnosis in February, 2011. Hologic systems are now in use in 48 states in the U.S. and over 50 countries.

    For more information about Hologic's 3D mammography technology, please visit www.BreastTomo.com (for healthcare providers) and www.Hologic3D.com (for patients).

    About Hologic, Inc.Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts.

    Hologic is a trademark and/or registered trademark of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

    Forward-Looking Statement Disclaimer.This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic digital mammography systems. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.ContactsMarianne  McMorrow

    Pat HallGlobal PR and Advertising Publicist

    Director of Corporate CommunicationsHologic, Inc.

    Hologic, Inc.Marianne.McMorrow@Hologic.com

    Pat.Hall@Hologic.com Tel: +1 781 999 7723

    Tel: +1 781 999 7463  [i] Rose SL, Tidwell AL, Bujnock LJ, Kushwaha AC, Nordmann AS, Sexton R Jr. Implementation of Breast Tomosynthesis in a Routine Screening Practice: An Observational Study.  American Journal of Roentgenology.  Published online in advance of print May 23, 2013.


    '/>"/>
    SOURCE Hologic, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System
    2. Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
    3. Medifirst Solutions, Inc. Announces Update To Shareholders
    4. Concord Medical Reports First Quarter 2013 Financial Results
    5. Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
    6. ConvaTec Announces 2013 First Quarter Earnings Call
    7. Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results
    8. A*STAR and Cytos Bring Singapores First Influenza Vaccine to Clinical Testing
    9. ULURU Inc. Reports First Quarter 2013 Financial Results
    10. Access Pharmaceuticals Reports First Quarter Results
    11. SOAPware President Randall Oates, M.D. Among First NCQA Certified Patient-Centered Medical Home Content Experts
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
    (Date:4/28/2016)... 2016 New market research ... a report that provides an overview of the ... by identifying new targets and MOAs to produce ... discussed in this H1 2016 Osteoarthritis Pipeline report ... Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, ...
    (Date:4/27/2016)... 2016   ... sur le trimestre, soutenu par une croissance de ... Croissance de +16% des ventes aux hôpitaux et ... Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de ... son chiffre d,affaires pour le premier trimestre clos ...
    Breaking Medicine Technology:
    (Date:5/2/2016)... ... May 02, 2016 , ... ... announced a new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies ... quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout ...
    (Date:5/2/2016)... ... May 02, 2016 , ... Visceral fat, also known as ... kidneys, liver and pancreas. If not properly addressed, visceral fat can lead to ... Medicine, Medical Oncology and Palliative Care, warns against the dangers of visceral fat. ...
    (Date:5/2/2016)... (PRWEB) , ... May 02, ... ... researchers report that many commonly used prescription medications, including anxiolytics, painkillers, antidepressants ... mitigate these risks, Novus Medical Detox Center —a leading Florida-based drug ...
    (Date:5/2/2016)... , ... May 02, 2016 , ... Pregnancy Awareness Month ... trying to conceive. , “If you are ready to have a baby, ... “My book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy Organizer, written ...
    (Date:5/2/2016)... , ... May 02, 2016 , ... ... and urgent care facilities designed to automate and improve the rapid diagnosis, triage ... it is demonstrating their platform, application, and mobile experience for the first time ...
    Breaking Medicine News(10 mins):